New Indication for Nubeqa: Metastatic Hormone-Sensitive Prostate Cancer
The approval was based on data from the phase 3 ARASENS trial.
Prostate Cancer
Pembrolizumab Combos Miss Primary Endpoints in Liver, Prostate Cancer Trials
The LEAP-002 study evaluated pembrolizumab plus lenvatinib in patients with uHCC; the KEYNOTE-921 study evaluated pembrolizumab plus docetaxel in patients with mCRPC.
Abiraterone and Enzalutamide Raise Metabolic, Cardiovascular Adverse Event Risks
A report in the Journal of the National Cancer Institute presents findings from the first assessment of the real-world safety of abiraterone and enzalutamide in a national sample of Medicare beneficiaries with advanced prostate cancer.
May 2022: Drug Pipeline Updates
Stay up-to-date on the latest drugs in development.
Darolutamide Plus Docetaxel Gets Priority Review for Metastatic Hormone-Sensitive Prostate Cancer
The sNDA is supported by data from the phase 3 ARASENS trial, which included1306 patients with mHSPC.
Camcevi Now Available for Advanced Prostate Cancer Treatment
Camcevi is a ready-to-use 6-month subcutaneous depot formulation of leuprolide mesylate, a gonadotropin-releasing hormone agonist.
Pluvicto Approved for PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
Pluvicto is a radioligand therapeutic agent containing the active moiety, lutetium-177, which binds to PSMA, a transmembrane protein that is expressed in prostate cancer.
Merck Halts Trial Evaluating Combo Therapy for Metastatic Castration-Resistant Prostate Cancer
Following a planned interim analysis, the decision to halt the trial was made after a review of data by an independent Data Monitoring Committee.
Niraparib With Abiraterone + Prednisone Improves Outcomes in HRR BM+ Metastatic Castration Resistant Prostate Cancer
The phase 3 MAGNITUDE study assessed niraparib in combination with abiraterone acetate plus prednisone in patients with mCRPC with or without alterations in homologous recombination repair associated genes.
Talabostat Plus Pembrolizumab Promising for mCRPC With Adenocarcinoma Phenotype
At a median follow-up of 12 weeks, results showed that the composite response rate was 23%.
